Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
-- Dr.
-- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy --
Mast cells are increasingly implicated in the pathogenesis of a wide range of allergic and inflammatory conditions, leading to an acceleration in research into mast cell biology. This webcast will focus on the biology of mast cells, including their essential role as drivers of and contributors to inflammatory responses, their core involvement in biological pathways relevant to an array of allergic and inflammatory diseases, and Blueprint's approach to modulating mast cells and building a pipeline in allergic and inflammatory disease. The webcast will include a presentation and live Q&A.
Title: The powerful mast cell: a promising target for treating allergic and inflammatory diseases
Date: Thursday, April 25, 2024
Time: 10:00 a.m. ET
Presenters:
Guest speaker
Mariana Castells , M.D., Ph.D., Director, Mastocytosis Center atBrigham and Women's Hospital
- Fouad Namouni, M.D., President, Research & Development
Becker Hewes , M.D., Chief Medical OfficerPercy H. Carter , Ph.D., MBA, Chief Scientific Officer
To access the live webcast, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 814168. A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of the
Blueprint plans to host the next webcast in the series in the second half of 2024.
About
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-host-webcast-and-conference-call-highlighting-emerging-opportunities-for-mast-cell-targeted-therapeutics-302113503.html
SOURCE
Investor Relations Contact: Cassie Saitow, 617.909.3127, ir@blueprintmedicines.com; Media Relations Contact: Andrew Law, 617.844.8205, media@blueprintmedicines.com